



USFDA completes inspection at Indoco Remedies' API manufacturing facility

Sep-19-2025

The United States Food and Drug Administration (USFDA) has successfully completed inspection at Indoco Remedies' Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai. The inspection concluded with zero form 483 observations, reflecting the company's commitment to the highest standards of quality, regulatory compliance and operational excellence.

This successful USFDA inspection is a testament to the strong quality culture and compliance in every process and every product. The company remains committed to strengthening its systems to deliver safe and efficacious medicines across the globe.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.